Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
162 hedge funds and large institutions have $2.46B invested in Blueprint Medicines in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 51 increasing their positions, 59 reducing their positions, and 37 closing their positions.
44% more call options, than puts
Call options by funds: $10.1M | Put options by funds: $7M
1.84% more ownership
Funds ownership: 102.2% → 104.04% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
14% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 59
14% less funds holding
Funds holding: 188 → 162 (-26)
30% less capital invested
Capital invested by funds: $3.5B → $2.46B (-$1.04B)
62% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$66.2M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$16.6M |
| 3 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$16.3M |
| 4 |
Alkeon Capital Management
New York
|
+$13.6M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$112M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$18.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$12.3M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$9.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$9.13M |
BPMC Hedge Fund Activity: Q4 2018 in Review
162 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2018, worth a combined $2.46B — down 30% from $3.5B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of BPMC and 14 opened new positions — a net loss of 23 holders — while 59 trimmed existing stakes and 51 added.
The largest buyer was Viking Global Investors, adding an estimated $66.2M. The largest seller was Hillhouse Investment Management, exiting entirely with an estimated $112M sold.
- 162 institutional investors held Blueprint Medicines (BPMC) as of Q4 2018, down from 188 in Q3 2018.
- Funds reported $2.46B of Blueprint Medicines stock for Q4 2018, down 30% quarter-over-quarter.
- 14 funds opened new Blueprint Medicines positions in Q4 2018 and 37 closed out, a net change of -23 holders.
- The largest Blueprint Medicines buyer in Q4 2018 was Viking Global Investors, an estimated $66.2M added.
- The largest Blueprint Medicines seller in Q4 2018 was Hillhouse Investment Management, an estimated $112M sold.
Based on aggregated 13F filings for Q4 2018.